Keyword: Changzhou

A Chinese maker of heparin and APIs for oncology and other drugs is investing nearly $150 million as it targets innovative drugs for China.

Changzhou Fangyuan Pharma is ready for clinical trials in China to test its nearly decade-long work on a tricky-to-make semisynthetic, methicillin-resistant and gram-negative infection-fighting antibiotic.